COMP <GO>
GKOS vs LLY // RSI-14 & 200D SMA MOMENTUM
Glaukos Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GKOS 3
— LLY 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: GKOS
LAST: $237.60 (-2.01%) • MKT CAP: $14.35B
rsi-technicals
82.6
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GKOS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GKOS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 83.64% | -27.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.70% | 32.36% | -46.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 2.30% | -2.46 | LLY | /fcf-yield <GO> |
| Operating Margin | -39.30% | 40.21% | -79.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | -37.00% | 31.90% | -68.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 32.30% | 45.51% | -13.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | GKOS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 82.6 | 77.9 | +4.70 | GKOS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.51 | +0.53 | GKOS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 26.3x | +7.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.35B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GKOS REV | LLY REV | GKOS GROSS % | LLY GROSS % | GKOS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $507.4M | $65.18B | 55.7% | 83.0% | -$22.5M | $16.81B |
| FY 2024 | $383.5M | $45.04B | 75.5% | 81.3% | -$67.6M | $8.82B |
| FY 2023 | $314.7M | $34.12B | 44.0% | 79.3% | -$71.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GKOS // BETA 1.04
LLY // BETA 0.51